LG Chem nets $200M con­tract to man­u­fac­ture sev­er­al vac­cines

The South Ko­re­an chem­i­cal and life sci­ence pro­duc­er LG Chem has roped in a mul­ti­mil­lion-dol­lar con­tract to pro­duce its po­lio vac­cine.

LG Chem has se­cured a man­u­fac­tur­ing con­tract worth $200 mil­lion for UNICEF to pro­duce its po­lio vac­cine called Eu­po­lio and the pen­tava­lent vac­cine Eu­pen­ta, which is de­signed to pre­vent diph­the­ria, tetanus, he­pati­tis B, menin­gi­tis and per­tus­sis.

LG Chem will pro­duce $100 mil­lion-worth of its po­lio vac­cine for two years, from 2024 through 2025. The con­tract for Eu­pen­ta will pro­duce $100 mil­lion-worth of the vac­cine for the next five years, start­ing this year through 2027. While no ex­act pro­duc­tion amounts were giv­en, LG Chem stat­ed in its re­lease that it will be sup­ply­ing vac­cines for around 80 mil­lion chil­dren glob­al­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER